Preladenant (previously known as SCH-420814) is an antagonist for adenosine A2A receptor with high affinity (Ki of 1.1 nM in vitro) and selectivity (>1000-fold over other adenosine receptos. It was initially developed by Schering-Plough as a potential treatment for Parkinson's disease. This Biotin-d(PEG)2-Preladenant conjugate was designed with a flexible PEG linker and synthesized at CellMosaic for our customer’s usage of detecting and characterizing A2AR receptor.nnThe final product is supplied as a DMSO solution at 5 mg/mL. nnThe product is sold as 1 vial of 1 mg (Cat# CM61008-1MG), 5 vials of 1 mg (Cat# CM61008-5MG), and 10 vials of 1 mg (Cat# CM61008-10MG). For bulk orders, please contact us for a quote.